Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks....

Full description

Bibliographic Details
Main Authors: Aharona Glatman-Freedman, Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2022-05-01
Series:Emerging Infectious Diseases
Subjects:
COVID-19
coronavirus disease
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
viruses
respiratory infections
Online Access:https://wwwnc.cdc.gov/eid/article/28/5/22-0141_article

Internet

https://wwwnc.cdc.gov/eid/article/28/5/22-0141_article

Similar Items